RJH Biosciences Inc.
RJH Biosciences Inc.Homepage
|RJH Biosciences is a biotechnology company based out of Edmonton, Alberta, Canada. We develop novel transfection reagents and delivery systems that transport different types of nucleic acids to a range of human cells and cell lines. We develop value-added products in two commercial segments, as transfection reagents for biomedical R&D enterprise and as nucleic acid delivery vehicles for preclinical and clinical applications. The same transfection reagents are used in our own R&D projects that focus on blood cancers and modification of immune cells.|
Products: Transfection Reagents
Summary of Reagents
Designed as a siRNA pDNA transfection reagent it can be used for either siRNA knockdown, plasmid DNA transformation or siRNA pDNA co-delivery. It is particularly suitable for mesenchymal stem cells from cord blood and bone marrow, and highly differentiated cells such as smooth muscle cells, and endothelial cells.
Download Information: All-Fect Brochure
Go to Store: View Product
Benefits of the reagent:
- High transfection efficiency
Provides 2 to 3-fold higher efficacy in the presences of serum
- Simple Protocol
No need to change tissue culture medium during transfection
Less toxic compared to commercial transfection reagents, leading to better retention of normal cellular physiology
- Hsu and Uludağ. Biomaterials (2012) 33: 7834-7848.
- Remant Bahadur et al., J. Materials Chemistry B (2015) 3: 3972-3982.
- Wang et al., J. Surgical Research (2013) 183: 8-17.
Images: Typical performance of All-Fect for transfecting cord-blood derived mesenchymal stem cells with a GFP plasmid. The study compared the performance of All-Fect against a leading lipofection reagent under conditions optimized for each reagent. The extent of transgene expression was quantitated by flow cytometry, based on the extent of EGFP expression in arbitrary units. Typical fluorescent micrographs showing GFP expression after transfection are provided on the top.
Feature of Products
We developed broadly acting transfection reagents to modify mammalian cells with plasmid DNA, siRNA, mRNA and other nucleic acids. The foundation of our transfection reagents is based on cationic lipopolymers with optimal balance of cationic charge and hydrophobic (lipid) group. By systematically altering the polymeric backbone and the nature of lipid group, a library of transfection reagents has been generated. Some of the transfection reagents are broadly acting, functioning in different cell types with different nucleic acids. Others display high specificity, where they are exceptionally effective in particular cell types for particular nucleic acid delivery.
The key advantages of our delivery vehicles are:
- Multivalent interactions with nucleic acids leading to strong binding of cargo that withstand disruptive forces in transit through cell membranes.
- Synergistic effects due to cationic and lipidic binding that coat the cargo and protect it from nucleases.
- Lipidic moieties that enhance interactions with cell memblane and internalization.
- pH buffering capacitythat facilitate escape of cargo from endosomes.
- Tailored formulations to free nucleic acids once internalized in cytoplasm.
The transfection reagents have been optimized for the following cell models and applications:
Background of Service
Our R&D Focus
One area of focus for RJH Biosciences is to implement RNA interference (RNAi) via delivery of short interfering RNA (siRNA). Our initial therapeutic application is blood cancers, while recognizing that the RNAi activity can be implemented in the treatment of a large range of human cancers and other diseases. Another focus is direct administration of plasmid DNA (pDNA) to express therapeutic proteins in situ, with applications in immunotherapy.
Why study blood cancers and immunotherapies with nucleic acid therapeutics?
There are three types of blood cancers: Leukemia, lymphoma, and myeloma. Leukemia is characterized by highly proliferating, abnormal white blood cells . Lymphoma and myeloma are respectively cancers of the lymphatic system and plasma cells which greatly effect the immune system [2,3]. These three cancers are difficult to treat and the current treatments are limited in efficacy, especially at the end stage of the disease.
The use of nucleic acid-based therapeutics can eradicate these cancers in two primary ways, with RNAi technology and cell-based immunotherapy. The use of RNAi is being increasingly explored in the treatment of the blood cancers. Polynucleotides such as siRNA has aided the downregulation of oncogenes and can be designed to support specific abnormalities in individual patients, making it a ‘personal’ strategy with a universal technological design . Due to siRNA’s potential in blood cancer therapies, we are currently focusing on siRNA therapeutics in our R&D projects, targeting disease-driving oncogenes and inducing apoptosis in the malignant cells.
Another strategy that is being explored for treating blood cancers is the use of immunotherapy. Immunotherapeutic strategies include the use of antibodies, stem cell transplants, cytokines, small molecules among others . However, a more recent approach is genetic therapy by using engineered cells, also known as Cell Transfer Therapy. This method works by taking patients’ own immune cells such as but not limited to T-cells, B-cells, and NK cells. The immune cells genome is engineered to support various therapeutic strategies that may involve neoantigen expression and presentation on immune cell surface, and then are reintroduced into the host . The modified cells are ultimately designed to target and remove the malignant cells. This strategy is highly advantageous as T-cells can ‘seek’ and destroy the malignant cells in the blood system. While this approach has been promising in blood cancers, it can be also used in other solid cancers. As the foundation of immunotherapy relies on nucleic acid introduction into patient cells, efficient delivery of nucleic acids is imperative for success. Our transfection reagents offer the best in class vehicles to undertake such a delivery.
Nanomedicine based on nucleic acid therapeutics is a large component to personalized cancer therapies and immunotherapies. The RJH Biosciences strives to provide quality transfection reagents, whether it involves the delivery of our own nucleic acid candidates or our customers’.
Woods, N. et al. (2006) Therapueti gene causing lymphoma. Nature. 440, 1123.
Mahindra, A. et al. (2012) Latest advances and current challenges in the treatment of multiple myeloma. Nature Reviews Clinical Oncology. 9, 135-143.
Uludağ, H. et al. (2016) Current attempts to implement siRNA-based RNAi in leukemia models. Drug Discovery Today. 21, 1412-1420.
Zou, W. (2006) Regulatory T cells, tumour immunity and immunotherapy. Nature Reviews Immunology. 6, 295-307.
|All-Fect||pDNA, siRNA and co-delivery reagents for a broad range of cells||0.75 ml/1.5 ml|
|Prime-Fect||Reagent of choice for tough to transfect primary and stem cells||0.75 ml/1.5 ml|
|Leu-Fect A & B||Specialized reagents leukemia and suspension cells||0.75 ml/1.5 ml|
|Trans-Booster||Designed to enhance the transfection efficiency of DNA/mRNA in attachment dependent and suspension-growing cells||0.75 ml/1.5 ml|
|In Vivo DNA-Fect||Effective for pDNA delivery in animal models and cells||0.75 ml/1.5 ml|
|In Vivo RNA-Fect||Effective systemic delivery of siRNA in animal models||0.75 ml/1.5 ml|
|mRNA-Fect||Highly effective transfection reagent optimized for mRNA delivery||0.75 ml/1.5 ml|
|CRISP-Fect||Highly effective transfection reagent optimized for ribonucleoprotein (RNP) delivery to both attachment-dependent and suspension-growing cells.||0.75 ml/1.5 ml|
Transfection Reagent Selection Guide
The table below summarizes optimal transfection reagents for nucleic acids in different cell types.
The efficiency of the transfection reagents was assessed by using plasmid DNA (pDNA), short interfering RNA (siRNA), and messenger RNA (mRNA).
Where the transfection reagent was suitable for both pDNA or siRNA delivery, it was indicated with pDNA/siRNA.
|Umbilical Cord Blood Derived Mesenchymal Stem Cells (UCB-MSC)||pDNA||pDNA
|Bone Marrow Derived Mesenchymal Stem Cells (BM-MSC)||pDNA||pDNA
|Vascular smooth muscle Cells (VSMCs)||pDNA
|Human Umbilical Vein Endothelial Cells (HUVECs)||pDNA
|Mononuclear Cells from CML patients (MNC)||pDNA
|Human Foreskin Fibroblast Cells||pDNA|
|Rat Primary Sympathetic Neurons||pDNA||mRNA|
|Kidney Fibroblast Cells (293-T)||pDNA||pDNA
|Breast Cancer Cells (MDA-MB-231)||pDNA
|Kidney Epithelial Cells (MDCK)||siRNA|
|Breast Cancer/Melanoma Cells (MDA-MB-436)||pDNA
|Breast Cancer Cells (MDA-MB-468)||siRNA|
|Breast Cancer Cells (Sum-149PT)||pDNA
|Breast Cancer Cells (MCF-7)||pDNA||pDNA
|Human Lymphoma Cells (U-937)||pDNA||pDNA|
|Chronic Myeloid Leukaemia Cells (K562)||siRNA||pDNA
|Acute Myeloid Leukemia Cells (KG1 and KG1A)||siRNA||siRNA|
|Acute Myeloid Leukemia Cells (THP1)||siRNA||siRNA||mRNA|
|Human Lung Cancer Cells (A549)||siRNA|
|Human Colon Cancer (HCT-116)||siRNA||siRNA|
Example of Use
Feedback from independent researchers
Implementing CRISPR-Cas9 Technology using Transfection Reagents from RJH Biosciences
Killing Lung Cancer A549 Cells with RJH Reagents and Cytotoxic siRNAs
mRNA Transfection of Endothelial Cells with RJH Reagents
Transfecting Human Astrocytes with RJH Reagents: GFP Expression and siRNA Uptake
Transfection of A549 Lung Cancer Cells with RJH Reagents to Silence Tumor Suppressor p53 Expression
Transfecting Colon Cancer HCT-116 Cells with RJH Reagents to silence Polynucleotide Kinase 3′-Phosphatase (PNKP) Expression
Use of RJH Transfection Reagents in Antisense Oligonucleotide Delivery
Reagents for pDNA and siRNA delivery for TNBC cells
Reagents for Antisense Oligonucleotide (ASO) Delivery
Comparing Lipofection to RJH Reagents
mRNA Modification of PBMCs
mRNA-Fect Transfection Reagent to Deliver mRNA in Breast Cancer Cells
Transfecting Triple-Negative Breast Cancer MDA-MB-231 Cells with Plasmid DNA and siRNA by using ALL-Fect and Prime-Fect
Use of RJH Transfection Reagents in Co-Delivery of Plasmid DNA and short interfering RNA
RJH Transfection Reagents in siRNA Library Screens
microRNA Delivery to Leukemic Cells
Back to Top
Please contact us for any inquiries, questions, or information requests.
Tokyo Future Style, Inc.